Meet Eli Lilly’s New Phase 3 Alzheimer’s Drug, Remternetug
Drugmaker Eli Lilly says experimental Alzheimer’s drug remternetug is part of the next generation of anti-amyloids. The approval of the controversial anti-amyloid drug Aduhelm…
Drugmaker Eli Lilly says experimental Alzheimer’s drug remternetug is part of the next generation of anti-amyloids. The approval of the controversial anti-amyloid drug Aduhelm…
How much does Aduhelm cost? Even if you can cover the expense, that doesn’t mean the drug is easy to get. Aduhelm costs an…
New findings reveal that the way Aduhelm is packaged leads to wasted medication — and as much as $605 million per year of Medicare…
The Centers for Medicare and Medicaid Services finalized its decision to limit the coverage of Alzheimer’s drug Aduhelm and future monoclonal antibodies. In February…
European drug regulators dealt a blow to Biogen, deciding against allowing Aduhelm onto the market. Meanwhile, the company slashed the price of its drug…
As an aducanumab trial participant, Phil Gutis, a reporter with early-stage Alzheimer’s, was part of Aduhelm’s journey to FDA approval. Doctors can soon start…
“Historic moment:” Today, the FDA gave Biogen’s investigational Alzheimer’s drug aducanumab its approval, with the requirement that they conduct a post-approval trial. In a…